Identification of budesonide metabolites in human urine after oral administration

Analytical and Bioanalytical Chemistry

Volumn 404, Issue 2, 2012, Pages 325-340

  Matabosch, Xavier ^a   Pozo, Oscar J ^a   Pérez Mañá, Clara ^b   Farré, Magi ^b   Marcos, Josep ^a,c,d   Segura, Jordi ^a,c,d   Ventura, Rosa ^c,d  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Budesonide; Doping analysis; Mass spectrometry; Metabolism; Urine

Indexed keywords

ACETAL GROUPS; BUDESONIDE; CARBONYL GROUPS; COLLISION INDUCED DISSOCIATION; DOPING ANALYSIS; DOPING CONTROL; ELECTRON IONIZATION; FREE FRACTION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDES; HUMAN URINE; HYDROXYL GROUPS; INFLAMMATORY BOWEL DISEASE; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; ORAL ADMINISTRATION; SCAN METHODS; SCAN MODE; STRUCTURAL INFORMATION; URINE; URINE SAMPLE;

BODY FLUIDS; DISEASES; GAS CHROMATOGRAPHY; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES; PHYSIOLOGY;

BIOMOLECULES;

BUDESONIDE; GLUCOCORTICOID;

CONFERENCE PAPER; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLISM; ORAL DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY; URINE;

ADMINISTRATION, ORAL; BUDESONIDE; CHROMATOGRAPHY, LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOCORTICOIDS; HUMANS; TANDEM MASS SPECTROMETRY;

EID: 84865474316     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6037-0     Document Type: Conference Paper

References (42)

1. Clissold SP, Heel RC (1984) Drugs 28:485-518
2. Brogden RN, McTavish D (1992) Drugs 44:375-407
3. McKeage K, Goa KL (2002) Drugs 62:2263-2282
4. The World Anti-Doping Code. The 2012 Prohibited List. International Standard (2011) World Anti-Doping Agency, Montreal, Canada. http://www.wada-ama. org/Documents/World-Anti-Doping-Program/WADP-Prohibited-list/2012/ WADA-Prohibited-List-2012-EN.pdf
5. 2010 Adverse analytical findings and atypical findings (2011) World Anti-Doping Agency, Montreal, Canada. http://www.wadaama.org/Documents/ Resources/Statistics/Laboratory-Statistics/WADA-2010-Laboratory-Statistics- Report.pdf
6. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E (1982) J Steroid Biochem 16:779-786
7. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R (1982) Eur J Respir Dis Suppl 122:86-95
8. Edsbacker S, Jonsson S, Lindberg C, Ryrfeldt A, Thalen A (1983) Drug Metab Dispos 11:590-596
9. Edsbacker S, Andersson P, Lindberg C, Paulson J, Ryrfeldt A, Thalen A (1987) Drug Metab Dispos 15:403-411
10. Deventer K, Delbeke FT (2003) Rapid Commun Mass Spectrom 17:2107-2114
11. Mazzarino M, Turi S, Botre F (2008) Anal Bioanal Chem 390:1389-1402
12. Parr MK, Schanzer W (2010) J Steroid Biochem Mol Biol 121:528-537
13. Mazzarino M, de La Torre X, Botre F, Gray N, Cowan D (2010) Drug Test Anal 2:311-322
14. Rodchenkov GM, Vedenin AN, Uralets VP, Semenov VA (1991) J Chromatogr 565:45-51
15. Rodchenkov GM, Uralets VP, Semenov VA, Gurevich VA (1988) J Chromatogr 432:283-289
16. Rodchenkov GM, Uralets VP, Semenov VA (1988) J Chromatogr 426:399-405
17. Rodchenkov GM, Uralets VP, Semenov VA (1987) J Chromatogr 423:15-22
18. Pozo OJ, Ventura R, Monfort N, Segura J, Delbeke FT (2009) J Mass Spectrom 44:929-944
19. Pozo OJ, Marcos J, Ventura R, Fabregat A, Segura J (2010) Anal Bioanal Chem 398:1759-1770
20. Gómez C, Pozo OJ, Geyer H, Marcos J, Thevis M, Schänzer W, Segura J, Ventura R. J Steroid Biochem Mol Biol (in press)
21. Pozo OJ, Marcos J, Matabosch X, Ventura R, Segura J (2012) Rapid Commun Mass Spectrom 26:541-553
22. Segura J, Ventura R, Jurado C (1998) J Chromatogr B: Biomed Sci Appl 713:61-90
23. Berges R, Segura J, de La Torre X, Ventura R (1999) J Chromatogr B: Biomed Sci Appl 723:173-184
24. Ventura R, Segura J, Berges R, Fitch KD, Morton AR, Berruezo S, Jimenez C (2000) Ther Drug Monit 22:277-282
25. Berges R, Segura J, Ventura R, Fitch KD, Morton AR, Farre M, Mas M, de La Torre X (2000) Clin Chem 46:1365-1375
26. Mareck U, Guddat S, Schwenke A, Beuck S, Geyer H, Flenker U, Elers J, Backer V, Thevis M, Schanzer W (2011) Drug Test Anal 3:820-827
27. Han CA, Monder C (1982) J Org Chem 47:1580-1584
28. Hou S, HindleM, Byron PR (2001) J Pharm Biomed Anal 24:371-380
29. Pozo OJ, Van EP, Deventer K, Grimalt S, Sancho JV, Hernandez F, Delbeke FT (2008) Rapid Commun Mass Spectrom 22:4009-4024
30. Pozo OJ, Lootens L, Van EP, Deventer K, Meuleman P, Leroux-Roels G, Parr MK, Schanzer W, Delbeke FT (2009) Drug Test Anal 1:554-567
31. Pozo OJ, Van EP, Deventer K, Lootens L, Van TW, Parr MK, Schanzer W, Sancho JV, Hernandez F, Meuleman P, Leroux-Roels G, Delbeke FT (2009) Drug Metab Dispos 37:2153-2162
32. Oueslati F, Siai A, Hentati E, Fenina N, Loueslati MH (2011) 29th Cologne Workshop on Dope Analysis
33. Shackleton CHL, Marcos J (2006) In: Gross M, Caprioli R (eds) The encyclopedia of mass spectrometry. Amsterdam, Elsevier
34. Schanzer W, Donike M (1992) Biol Mass Spectrom 21:3-16
35. Masse R, Bi HG, Ayotte C, Du P, Gelinas H, Dugal R (1991) J Chromatogr 562:323-340
36. Meloche CA, Sharma V, Swedmark S, Andersson P, Falany CN (2002) Drug Metabolism and Disposition 30:582-585
37. White PC, Agarwal AK, Nunez BS, Giacchetti G, Mantero F, Stewart PM (2000) Endocr Res 26:771-780
38. Jonsson G, Astrom A, Andersson P (1995) Drug Metab Dispos 23:137-142
39. Assandri A, Ferrari P, Perazzi A, Ripamonti A, Tuan G, Zerilli L (1983) Xenobiotica 13:185-196
40. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ (1996) J Pharmacol Exp Ther 277:105-112
41. Roberts S, Szego CM (1955) Annu Rev Biochem 24:543-596
42. Jin Y (2011) Chem Biol Interact 191:234-238